Pfizer Inc (PFE) 33.97 $PFE
Allergan (AGN) Gets FDA Nod for Avycaz Label Expansion
Arpita Dutt - Zacks Investment Research - Fri Jun 24, 8:12AM CDT
Allergan (AGN) is working on expanding the label of several of its approved products.
AGN: 225.72 (-7.79), PFE: 33.97 (-0.62), TEVA: 50.01 (-1.36), AMPH: 15.61 (-0.54)
Retrophin (RTRX) RE-024 Positive in Physician-Initiated Study
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 5:54AM CDT
Retrophin (RTRX) announced new data from a physician-initiated study on RE-024 for the treatment of pantothenate kinase-associated neurodegeneration (PKAN).
ANIP: 54.34 (-1.93), PFE: 33.97 (-0.62), RTRX: 17.80 (-0.69), ORPN: 1.72 (-0.02)
Why Pfizer (PFE) is a Great Stock to Buy for the Long Run
Maher Syed - Zacks Investment Research - Thu Jun 23, 7:37PM CDT
Pfizer has a great dividend, and it generates an incredibly high level of sales, but here's why else this stock is worth keeping in your portfolio for the long haul.
AGN: 225.72 (-7.79), PFE: 33.97 (-0.62), ANAC: 99.06 (-0.14)
Pfizer Declares 30-Cent Third-Quarter 2016 Dividend
BusinessWire - Thu Jun 23, 3:00PM CDT
The board of directors of Pfizer Inc. today declared a 30-cent third-quarter 2016 dividend on the company's common stock, payable September 1, 2016, to shareholders of record at the close of business on August 5, 2016. The third-quarter 2016 cash dividend will be the 311th consecutive quarterly dividend paid by Pfizer.
PFE: 33.97 (-0.62)
AstraZeneca Nasal Spray Flu Vaccine To be Hit By ACIP Vote
Arpita Dutt - Zacks Investment Research - Thu Jun 23, 8:15AM CDT
With the ACIP voting that AstraZeneca's (AZN) FluMist Quadrivalent should not be used in the 2016-2017 flu season, demand will be limited.
JNJ: 115.63 (-1.75), PFE: 33.97 (-0.62), AZN: 27.86 (-1.43), GSK: 40.80 (-1.76)
Nymox (NYMX) Stock Up on Positive 7-Year Fexapotide Data
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 7:51AM CDT
Nymox (NYMX) announced positive results from the seven-year, prospective, placebo-controlled, double-blind study on fexapotide (NX-1207).
ANIP: 54.34 (-1.93), PFE: 33.97 (-0.62), RTRX: 17.80 (-0.69), NYMX: 3.16 (+0.25)
Epizyme Teams Up with Roche's Genentech for Tazemetostat
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 7:32AM CDT
Epizyme (EPZM) announced that it has entered into a collaboration agreement with Roche's (RHHBY) Genentech to evaluate tazemetostat, in combination Tecentriq.
ANIP: 54.34 (-1.93), PFE: 33.97 (-0.62), EPZM: 9.85 (-0.59)
RedHill (RDHL) Stock Up on Positive Phase I Data on Yeliva
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 9:11AM CDT
RedHill (RDHL) announced positive results from a phase I study on Yeliva for the treatment of advanced solid tumors.
RDHL: 10.59 (-0.28), ANIP: 54.34 (-1.93), PFE: 33.97 (-0.62), BMY: 70.61 (-2.03)
7 Profitable Medical Stocks Ranked as Buys Now
Arpita Dutt - Zacks Investment Research - Tue Jun 21, 2:52PM CDT
It may be tough going for medical stocks but these 7 companies sporting a favorable Zacks Rank are poised to generate profits this year.
ZTS: 46.51 (-1.39), JNJ: 115.63 (-1.75), PFE: 33.97 (-0.62), LGND: 111.79 (-3.32), BMY: 70.61 (-2.03), AMPH: 15.61 (-0.54)
Vical (VICL) Reports Phase I/II Data on Genital Herpes Vaccine
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 9:12AM CDT
Vical (VICL) presented data from a phase I/II study on its investigational genital herpes vaccine at a meeting of the American Society for Microbiology.
VICL: 4.47 (-0.13), ANIP: 54.34 (-1.93), PFE: 33.97 (-0.62), BMY: 70.61 (-2.03)
Roger Ulrich Joins Board of Remedy Pharmaceuticals
BusinessWire - Tue Jun 21, 9:00AM CDT
Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing life-saving hospital-based treatment to people affected by central nervous system (CNS) related edema, today announced that Roger Ulrich has joined the company's board of directors.
GILD: 80.47 (-2.90), PFE: 33.97 (-0.62), MRK: 55.88 (-1.80), AZN: 27.86 (-1.43)
Rx pizza: 1 free meal can sway doctor prescribing
By LINDSEY TANNER - AP - Mon Jun 20, 2:16PM CDT
CHICAGO (AP) — As little as one free meal from a drug company can influence which medicines doctors prescribe for Medicare patients, according to a study using Medicare records and recently released data from the health care law's Open Payments program.
PFE: 33.97 (-0.62)
Epizyme Offers Early Data on Non-Hodgkin Lymphoma Drug
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 2:05PM CDT
Epizyme, Inc. (EPZM) reported encouraging preliminary data from its ongoing, global phase II trial on lead pipeline candidate, tazemetostat, at the American Society of Hematology Meeting on Lymphoma Biology.
ABT: 37.91 (-1.72), PFE: 33.97 (-0.62), EPZM: 9.85 (-0.59), BMY: 70.61 (-2.03)
Stock Market News for June 20, 2016
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 9:10AM CDT
Looming Brexit fears and Fed not hiking rates this month dragged benchmarks down on Friday, eventually finishing out the week lower
JNJ: 115.63 (-1.75), PXD: 152.92 (-7.67), V: 75.05 (-3.18), FB: 112.08 (-3.00), UNH: 137.29 (-1.90), MRK: 55.88 (-1.80), PFE: 33.97 (-0.62), EOG: 81.06 (-3.44), GOOGL: 685.20 (-29.67), CVX: 101.90 (-2.54), MSFT: 49.83 (-2.08), SLB: 76.66 (-2.93)
Emergent (EBS) BioThrax sBLA Accepted for FDA Review
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 8:13AM CDT
Emergent BioSolutions (EBS) announced that the FDA has accepted to review the company's sBLA for manufacturing BioThrax in Building 55.
EBS: 29.34 (-1.31), ANIP: 54.34 (-1.93), PFE: 33.97 (-0.62), BMY: 70.61 (-2.03)
U.S. Court Appoints Ernest Cory Lead Plaintiffs' Counsel In Viagra Melanoma MDL
PRWeb - Fri Jun 17, 1:41PM CDT
The Honorable Richard Seeborg has appointed Ernest Cory Plaintiffs' Lead Counsel in the federal multidistrict litigation, In re: Viagra (Sildenafil Citrate) Products Liability Litigation, MDL No. 2691. On June 15, 2016, In United States District Court in the Northern District of California, Judge Seeborg appointed fifteen attorneys from across the U.S., including Cory Watson, P.C. Principal Kristian Rasmussen to the Plaintiffs' Executive Committee. The U.S. Judicial Panel on Multidistrict Litigation (JPML) had transferred all pending federal Viagra lawsuits across the country to Judge Seeborg's court in the Northern District of California.
PFE: 33.97 (-0.62)
Look for Shares of Pfizer to Potentially Rebound after Yesterday's 1.25% Sell Off
Comtex SmarTrend(R) - Fri Jun 17, 12:03PM CDT
Pfizer (NYSE
FE) traded in a range yesterday that spanned from a low of $34.06 to a high of $34.81. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $34.42 on volume of 13.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
PFE: 33.97 (-0.62)
Paratek Reports Positive Phase III Data on Antibiotic Drug
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 10:03AM CDT
Paratek Pharmaceuticals (PRTK) announced positive phase III results on omadacycline for the treatment of acute bacterial skin and skin structure infections.
AGN: 225.72 (-7.79), PFE: 33.97 (-0.62), PRTK: 12.86 (-0.56)
Medivation's (MDVN) Pidilizumab Positive in Phase I/II Study
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 8:56AM CDT
Medivation (MDVN) announced data from a phase I/II study on pidilizumab for the treatment of pediatric with diffuse intrinsic pontine glioma.
MDVN: 56.95 (-2.31), ANIP: 54.34 (-1.93), PFE: 33.97 (-0.62), BMY: 70.61 (-2.03)
Don't Make it Complicated, Own Drug Stocks
John Blank - Zacks Investment Research - Thu Jun 16, 6:46PM CDT
The Large Cap Pharma Industry usually looks like a solid investor niche. Place a few of your stock picking bets here.
PFE: 33.97 (-0.62), BMY: 70.61 (-2.03)
Allergan (AGN) Gets FDA Nod for Avycaz Label Expansion
Arpita Dutt - Zacks Investment Research - Fri Jun 24, 8:12AM CDT
Allergan (AGN) is working on expanding the label of several of its approved products.
AGN: 225.72 (-7.79), PFE: 33.97 (-0.62), TEVA: 50.01 (-1.36), AMPH: 15.61 (-0.54)
Retrophin (RTRX) RE-024 Positive in Physician-Initiated Study
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 5:54AM CDT
Retrophin (RTRX) announced new data from a physician-initiated study on RE-024 for the treatment of pantothenate kinase-associated neurodegeneration (PKAN).
ANIP: 54.34 (-1.93), PFE: 33.97 (-0.62), RTRX: 17.80 (-0.69), ORPN: 1.72 (-0.02)
Why Pfizer (PFE) is a Great Stock to Buy for the Long Run
Maher Syed - Zacks Investment Research - Thu Jun 23, 7:37PM CDT
Pfizer has a great dividend, and it generates an incredibly high level of sales, but here's why else this stock is worth keeping in your portfolio for the long haul.
AGN: 225.72 (-7.79), PFE: 33.97 (-0.62), ANAC: 99.06 (-0.14)
Pfizer Declares 30-Cent Third-Quarter 2016 Dividend
BusinessWire - Thu Jun 23, 3:00PM CDT
The board of directors of Pfizer Inc. today declared a 30-cent third-quarter 2016 dividend on the company's common stock, payable September 1, 2016, to shareholders of record at the close of business on August 5, 2016. The third-quarter 2016 cash dividend will be the 311th consecutive quarterly dividend paid by Pfizer.
PFE: 33.97 (-0.62)
AstraZeneca Nasal Spray Flu Vaccine To be Hit By ACIP Vote
Arpita Dutt - Zacks Investment Research - Thu Jun 23, 8:15AM CDT
With the ACIP voting that AstraZeneca's (AZN) FluMist Quadrivalent should not be used in the 2016-2017 flu season, demand will be limited.
JNJ: 115.63 (-1.75), PFE: 33.97 (-0.62), AZN: 27.86 (-1.43), GSK: 40.80 (-1.76)
Nymox (NYMX) Stock Up on Positive 7-Year Fexapotide Data
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 7:51AM CDT
Nymox (NYMX) announced positive results from the seven-year, prospective, placebo-controlled, double-blind study on fexapotide (NX-1207).
ANIP: 54.34 (-1.93), PFE: 33.97 (-0.62), RTRX: 17.80 (-0.69), NYMX: 3.16 (+0.25)
Epizyme Teams Up with Roche's Genentech for Tazemetostat
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 7:32AM CDT
Epizyme (EPZM) announced that it has entered into a collaboration agreement with Roche's (RHHBY) Genentech to evaluate tazemetostat, in combination Tecentriq.
ANIP: 54.34 (-1.93), PFE: 33.97 (-0.62), EPZM: 9.85 (-0.59)
RedHill (RDHL) Stock Up on Positive Phase I Data on Yeliva
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 9:11AM CDT
RedHill (RDHL) announced positive results from a phase I study on Yeliva for the treatment of advanced solid tumors.
RDHL: 10.59 (-0.28), ANIP: 54.34 (-1.93), PFE: 33.97 (-0.62), BMY: 70.61 (-2.03)
7 Profitable Medical Stocks Ranked as Buys Now
Arpita Dutt - Zacks Investment Research - Tue Jun 21, 2:52PM CDT
It may be tough going for medical stocks but these 7 companies sporting a favorable Zacks Rank are poised to generate profits this year.
ZTS: 46.51 (-1.39), JNJ: 115.63 (-1.75), PFE: 33.97 (-0.62), LGND: 111.79 (-3.32), BMY: 70.61 (-2.03), AMPH: 15.61 (-0.54)
Vical (VICL) Reports Phase I/II Data on Genital Herpes Vaccine
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 9:12AM CDT
Vical (VICL) presented data from a phase I/II study on its investigational genital herpes vaccine at a meeting of the American Society for Microbiology.
VICL: 4.47 (-0.13), ANIP: 54.34 (-1.93), PFE: 33.97 (-0.62), BMY: 70.61 (-2.03)
Roger Ulrich Joins Board of Remedy Pharmaceuticals
BusinessWire - Tue Jun 21, 9:00AM CDT
Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing life-saving hospital-based treatment to people affected by central nervous system (CNS) related edema, today announced that Roger Ulrich has joined the company's board of directors.
GILD: 80.47 (-2.90), PFE: 33.97 (-0.62), MRK: 55.88 (-1.80), AZN: 27.86 (-1.43)
Rx pizza: 1 free meal can sway doctor prescribing
By LINDSEY TANNER - AP - Mon Jun 20, 2:16PM CDT
CHICAGO (AP) — As little as one free meal from a drug company can influence which medicines doctors prescribe for Medicare patients, according to a study using Medicare records and recently released data from the health care law's Open Payments program.
PFE: 33.97 (-0.62)
Epizyme Offers Early Data on Non-Hodgkin Lymphoma Drug
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 2:05PM CDT
Epizyme, Inc. (EPZM) reported encouraging preliminary data from its ongoing, global phase II trial on lead pipeline candidate, tazemetostat, at the American Society of Hematology Meeting on Lymphoma Biology.
ABT: 37.91 (-1.72), PFE: 33.97 (-0.62), EPZM: 9.85 (-0.59), BMY: 70.61 (-2.03)
Stock Market News for June 20, 2016
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 9:10AM CDT
Looming Brexit fears and Fed not hiking rates this month dragged benchmarks down on Friday, eventually finishing out the week lower
JNJ: 115.63 (-1.75), PXD: 152.92 (-7.67), V: 75.05 (-3.18), FB: 112.08 (-3.00), UNH: 137.29 (-1.90), MRK: 55.88 (-1.80), PFE: 33.97 (-0.62), EOG: 81.06 (-3.44), GOOGL: 685.20 (-29.67), CVX: 101.90 (-2.54), MSFT: 49.83 (-2.08), SLB: 76.66 (-2.93)
Emergent (EBS) BioThrax sBLA Accepted for FDA Review
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 8:13AM CDT
Emergent BioSolutions (EBS) announced that the FDA has accepted to review the company's sBLA for manufacturing BioThrax in Building 55.
EBS: 29.34 (-1.31), ANIP: 54.34 (-1.93), PFE: 33.97 (-0.62), BMY: 70.61 (-2.03)
U.S. Court Appoints Ernest Cory Lead Plaintiffs' Counsel In Viagra Melanoma MDL
PRWeb - Fri Jun 17, 1:41PM CDT
The Honorable Richard Seeborg has appointed Ernest Cory Plaintiffs' Lead Counsel in the federal multidistrict litigation, In re: Viagra (Sildenafil Citrate) Products Liability Litigation, MDL No. 2691. On June 15, 2016, In United States District Court in the Northern District of California, Judge Seeborg appointed fifteen attorneys from across the U.S., including Cory Watson, P.C. Principal Kristian Rasmussen to the Plaintiffs' Executive Committee. The U.S. Judicial Panel on Multidistrict Litigation (JPML) had transferred all pending federal Viagra lawsuits across the country to Judge Seeborg's court in the Northern District of California.
PFE: 33.97 (-0.62)
Look for Shares of Pfizer to Potentially Rebound after Yesterday's 1.25% Sell Off
Comtex SmarTrend(R) - Fri Jun 17, 12:03PM CDT
Pfizer (NYSE
FE) traded in a range yesterday that spanned from a low of $34.06 to a high of $34.81. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $34.42 on volume of 13.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. PFE: 33.97 (-0.62)
Paratek Reports Positive Phase III Data on Antibiotic Drug
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 10:03AM CDT
Paratek Pharmaceuticals (PRTK) announced positive phase III results on omadacycline for the treatment of acute bacterial skin and skin structure infections.
AGN: 225.72 (-7.79), PFE: 33.97 (-0.62), PRTK: 12.86 (-0.56)
Medivation's (MDVN) Pidilizumab Positive in Phase I/II Study
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 8:56AM CDT
Medivation (MDVN) announced data from a phase I/II study on pidilizumab for the treatment of pediatric with diffuse intrinsic pontine glioma.
MDVN: 56.95 (-2.31), ANIP: 54.34 (-1.93), PFE: 33.97 (-0.62), BMY: 70.61 (-2.03)
Don't Make it Complicated, Own Drug Stocks
John Blank - Zacks Investment Research - Thu Jun 16, 6:46PM CDT
The Large Cap Pharma Industry usually looks like a solid investor niche. Place a few of your stock picking bets here.
PFE: 33.97 (-0.62), BMY: 70.61 (-2.03)
